In its new study, ESOMAR-certified market research and consulting firm Future Market Insights (FMI), the worldwide peptide therapeutics market share currently valued at US$ 34.4 billion, is anticipated to grow at a remarkable CAGR of 11% from 2022 to 2025, reaching US$ 47 billion.

Peptide therapeutics demand are witnessing substantial demand, owing to increasing application in the treatment of various chronic disease such as cancer, cardiovascular diseases, hematologic diseases, and gastro-intestinal diseases.

Rising prevalence of these chronic diseases across the world is further expected to widen the existing patient pool. Therapeutic efficacy of peptide therapeutics is relatively superior as compared to other marketed drugs, resulting in their higher adoption among physicians.

The global peptide therapeutics market was valued at US$ 25.6 Bn in 2021, and is expected to exhibit a healthy CAGR of 11% during the forecast period (2022-2025).

The COVID-19 pandemic has been severely affecting the global economic order, and, in turn, the peptide therapeutics market. Restrictions on traveling, self-quarantines, and social distancing regulations, on a national scale, are resulting in notable drop in business and consumer spending through Q2.

Key Takeaways of Peptide Therapeutics Market Study

  • In terms revenue generation, among the applications, cancer outperformed other application types, owing to greater prevalence of the disease as well as higher efficacy of peptide therapeutics in cancer treatment.
  • Various peptide therapeutics are patented, and, in the mid of this decade, a majority of these patents are expected to reach their expiry dates, leading to higher generic competition.
  • Parenteral route continues to hold the leading revenue share in the peptide therapeutics market, owing to effective drug delivery and higher therapeutic index.

Key Players Focus on Strategic Collaborations and Generic Launches to Widen Regional Presence

Top peptide therapeutics companies are:

Eli Lilly and Company
AstraZeneca plc
Merck & Co. Inc
Ipsen S.A
Novo Nordisk A/S
Teva Pharmaceutical Industries Ltd. 

are concentrating on business expansions through joint ventures and distribution agreements, and are capturing untapped market potential.

Additionally, market incumbents are entering into collaborations in order to expand their regional presence and manufacturing capabilities in the global peptide therapeutics market.

More Valuable Insights on Peptide Therapeutics Market

Future Market Insights brings a comprehensive research report on forecasted revenue growth at global, regional, and country levels, and provides an analysis of the latest industry trends in each of the segments from 2014 to 2025. The global peptide therapeutics market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

For more Information @ 

The study provides compelling insights on the peptide therapeutics market on the basis of application, (cancer, cardiovascular diseases, central nervous systems, metabolic disorders, infection, hematological disorders, gastrointestinal disorders, dermatology, respiratory disorders, acromegaly, and other applications), route of administration (parenteral route, mucosal route, oral route, and transdermal route), and marketing (branded and generic), across seven major regions.

Key Segments Of Peptide Therapeutics Market Industry Survey

By Application :

  • Cancer
  • Cardiovascular Diseases
  • Central Nervous Systems
  • Metabolic Disorders
  • Infections
  • Hematological Disorders
  • Gastrointestinal Disorders
  • Dermatology
  • Respiratory Disorders
  • Acromegaly
  • Other Applications

By Route of Administration :

  • Parenteral Route of Administration
  • Mucosal Route of Administration
  • Oral Route of Administration
  • Transdermal of Route Administration

By Drug Type :

  • Branded Drugs
  • Generic/Biosimilar Drugs